Winslow Garrett 4

What Happened

• Winslow Garrett, General Counsel of Damora Therapeutics (DMRA), received a grant of a derivative award representing the right to purchase 250,000 shares on March 23, 2026. The award was recorded at $0.00 (no cash paid at grant) and is reported as an "A" (award/acquisition) transaction on Form 4. This is a compensation/retention award, not an open‑market purchase or immediate sale.

Key Details

• Transaction date: 2026-03-23; Form 4 filed: 2026-03-25 (timely filing).
• Instrument: derivative option/award for 250,000 shares; grant price reported $0.00 (no cash exchanged at grant).
• Vesting (footnote): 25% vests on March 23, 2027, then the remainder vests in equal monthly installments through March 23, 2030, contingent on continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant. No indication of 10b5-1 plan, tax withholding sale, or late filing.

Context

• This is an option-style award (a right to purchase shares) rather than an immediate stock purchase or sale. The award will only convert into actual shares if and when vested and exercised according to the vesting schedule.
• Such grants are commonly used for compensation and retention and do not, by themselves, signal immediate insider buying or selling of stock.